Shiga Toxins of Shigella dysenteriae and Escherichia coli

  • A. R. Melton-Celsa
  • A. D. O’Brien
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 145)


The Shiga toxins constitute a family of functionally and structurally related toxins produced by Shigella dysenteriae type 1 (also called Shiga’s bacillus) and a subset of diarrheagenic Escherichia coli called STEC (for Shiga toxin-producing E. coli). Shiga toxins of STEC were formerly called Shiga-like toxins and are alternatively named Vero toxins (Calderwood et al. 1996; Karmali et al. 1996). We favor the Shiga-toxin nomenclature system based largely on historical precedence. Indeed, the prototype for the Shiga-toxin family, Shiga toxin produced by S. dysenteriae type 1, was first described in 1903 by Conradi (Conradi 1903) and, independently, by Neisser and Shiga (Neisser and Shiga 1903). Conradi made the seminal observation that lysates of Shiga’s bacillus caused hind-leg paralysis when injected into rabbits.


Hemolytic Uremic Syndrome Coli Strain Shiga Toxin Shigella Dysenteriae Hemorrhagic Colitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Acheson DW, Keusch GT (1994) The Shigella paradigm and colitis due to enterohaemorrhagic Escherichia coli. Gut 35: 872–874PubMedCrossRefGoogle Scholar
  2. Austin PR, Jablonski PE, Bohach GA, Dunker AK, Hovde CJ (1994) Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity. Infect Immun 62: 1768–1775PubMedGoogle Scholar
  3. Barrett TJ, Green JH, Griffin PM, Pavia AT, Ostroff SM, Wachsmuth IK (1991) Enzyme-linked immunosorbent assays for detecting antibodies to Shiga-like toxin I, Shiga-like toxin II, and Escherichia coli 0157:H7 lipopolysaccharide in human serum. Curr Microbiol 23: 189–195CrossRefGoogle Scholar
  4. Bitzan M, Klemt M, Steffens R, Muller—Wiefel DE (1993) Differences in Verotoxinneutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection 21: 140–145PubMedCrossRefGoogle Scholar
  5. Burgess BJ, Roberts LM (1993) Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the Escherichia coli Shiga-like toxin I A subunit is not essential for cytotoxicity. Mol Microbiol 10: 171–179PubMedCrossRefGoogle Scholar
  6. Butterton JR, Calderwood SB (1998) Live, oral attenuated vaccine vectors for prevention of Shiga-toxin-producing Escherichia coli infection. In: Kaper JB, O’Brien AD (eds) Escherichia coli 0157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 425–433Google Scholar
  7. Calderwood SB, Mekalanos JJ (1987) Iron regulation of Shiga-like-toxin expression in Escherichia coli is mediated by the fur locus. J Bacteriol 169: 4759–4764PubMedGoogle Scholar
  8. Calderwood SB, Mekalanos JJ (1988) Confirmation of the Fur operator site by insertion of a synthetic oligonucleotide into an operon fusion plasmid. J Bacteriol 170: 1015–1017PubMedGoogle Scholar
  9. Calderwood SB, Auclair F, Donohue—Rolfe A, Keusch G, Mekalanos JJ (1987) Nucleotide sequence of the Shiga—like toxin genes of Escherichia coli. Proc Natl Acad Sci USA 84: 4364–4368CrossRefGoogle Scholar
  10. Calderwood SB, Acheson DWK, Keusch GT, Barrett TJ, Griffin PM, Strockbine NA, Swaminathan B, Kaper JB, Levine MM, Kaplan BS, Karch H, O’Brien AD, Obrig TG,Takeda Y, Tarr PI, Wachsmuth IK (1996) Proposed new nomenclature for SET ( VT) family. Amer Soc for Microbiol News 62: 118–119Google Scholar
  11. Caprioli A, Luzzi I, Rosmini F, Pasquini P, Cirrincione R, Gianviti A, Matteucci MC, Rizzoni G (1992) Hemolytic—uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. J Infect Dis 166: 154–158PubMedCrossRefGoogle Scholar
  12. Clark C, Bast D, Sharp AM, St.Hilaire PM, Agha R, Stein PE, Toone EJ, Read RJ, Brunton JL (1996) Phenylalanine 30 plays an important role in receptor binding of verotoxin-1. Mol Microbiol 19: 891–899PubMedCrossRefGoogle Scholar
  13. Conradi H (1903) Uber Iosliche, durch asptische Autolyse erhaltene Giftstoffe vonRuhr— and Typhus—Bazillen. Dtsch Med Wochenschr 29: 26–28CrossRefGoogle Scholar
  14. Cummings MD, Ling H, Armstrong GD, Brunton JL, Read RJ (1998) Modeling the carbohydrate-binding specificity of pig edema toxin. Biochemistry 37: 1789–1799PubMedCrossRefGoogle Scholar
  15. De Grandis S, Ginsberg J, Toone M, Climie S, Friesen J, Brunton J (1987) Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol 169: 4313–4319PubMedGoogle Scholar
  16. De Grandis S, Laws H, Brunton J, Gyles C, Lingwood CA (1989) Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem 264: 12520–12525Google Scholar
  17. Deresiewicz RL, Calderwood SB, Robertus JD, Collier RJ (1992) Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry 31: 3272–3280PubMedCrossRefGoogle Scholar
  18. Deresiewicz RL, Austin PR, Hovde CJ (1993) The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. Mol Gen Genet 241: 467–473PubMedCrossRefGoogle Scholar
  19. Dubos RJ, Geiger JW (1946) Preparation and properties of Shiga toxin and toxoid. J Exp Med 84: 143–156CrossRefGoogle Scholar
  20. Edwards AC, Melton-Celsa AR, Arbuthnott K, et al. (1998) Vero cell neutralization and mouse-protective efficacy of humanized monoclonal antibodies against Escherichia colt toxins Stxl and Stx2. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington DC, pp 388–392Google Scholar
  21. Endo Y, Mitsui K, Motizuki M, Tsurugi K (1987) The mechanism of action of ricin and related toxic lectins on eucaryotic ribosomes. J Biol Chem 262: 5908–5912PubMedGoogle Scholar
  22. Fenwick BW, Cowan LA (1998) Canine model of the hemolytic uremic syndrome. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxinproducing E. coli. ASM Press, Washington, DC, pp 268–277Google Scholar
  23. Fontaine A, Arondel J, Sansonetti P (1988) Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a tox-mutant of Shigella dysenteriae 1. Infect Immun 56: 3099–3109PubMedGoogle Scholar
  24. Fraser ME, Chernaia MM, Kozlov YV, James MNG (1994) Crystal structure of theGoogle Scholar
  25. holotoxin from Shigella dysenteriae at 2.5-A resolution. Structural Biology 1:59–64 Garred O, Van Deurs B, Sandvig K (1995) Furin-induced cleavage and activation ofGoogle Scholar
  26. Shiga toxin. J Biol Chem 270:10817–10821Google Scholar
  27. Garred O, Dubinina E, Polesskaya A, Olsnes S, Kozlov J, Sandvig K (1997) Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J Biol Chem 272: 11414–11419PubMedCrossRefGoogle Scholar
  28. Gordon VM, Whipp SC, Moon I1W, O’Brien AD, Samuel JE (1992) An enzymatic mutant of Shiga-like-toxin II variant is a vaccine candidate for ed.mta disease of swine. Infect Immun 60: 485–490Google Scholar
  29. Griffin PM (1995) Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli. In: Blaser MJ, Smith PD, Ravdin JI, et al. Infections of the gastrointestinal tract. Raven Press, Ltd. New York, pp 739–761Google Scholar
  30. Haddad JE, Jackson MP (1993) Identification of the Shiga toxin A subunit residues required for holotoxin assembly. J Bacteriol 175: 7652–7657PubMedGoogle Scholar
  31. Haddad JE, Al-Jaufy AY, Jackson MP (1993) Minimum domain of the Shiga-toxin A subunit required for enzymatic activity. J Bacteriol 175: 4970–4978PubMedGoogle Scholar
  32. Hovde CJ, Calderwood SB, Mekalanos JJ, Collier RJ (1988) Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc Natl Acad Sci USA 85: 2568–2572PubMedCrossRefGoogle Scholar
  33. Inward CD, Williams J, Chant I, Crocker J, Milford DV, Rose PE, Taylor CM (1995) Verocytotoxin-1 induces apoptosis in Vero cells. J Infect 30: 213–218PubMedCrossRefGoogle Scholar
  34. Ito H, Terai A, Kurazono H, Takeda Y, Nishibuchi M (1990) Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb Pathog 8: 47–60PubMedCrossRefGoogle Scholar
  35. Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT (1986) Pathogenesis of Shigella diarrhea. XI. Isolation of a Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163: 1391–1404PubMedCrossRefGoogle Scholar
  36. Jackson MP, Neill RJ, O’Brien AD, Holmes RK, Newland JW (1987a) Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 44: 109–114CrossRefGoogle Scholar
  37. Jackson MP, Newland JW, Holmes RK, O’Brien AD (1987b) Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog 2: 147–153PubMedCrossRefGoogle Scholar
  38. Jackson MP, Deresiewicz RL, Calderwood SB (1990a) Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits. J Bacteriol 172: 3346–3350PubMedGoogle Scholar
  39. Jackson MP, Wadolkowski EA, Weinstein DL, Holmes RK, O’Brien AD (1990b) Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis. J Bacteriol 172: 653–658PubMedGoogle Scholar
  40. Jemal C, Haddad JE, Begum D, Jackson MP (1995) Analysis of Shiga toxin subunit association by using hybrid A polypeptides and site-specific mutagenesis. J Bacteriol 177: 3128–3132PubMedGoogle Scholar
  41. Johnson WM, Lior H, Bezanson GS (1983) Cytotoxic Escherichia coli 0157:H7 associated with haemorrhagic colitis in Canada. Lancet 1: 76PubMedCrossRefGoogle Scholar
  42. Kaplan BS, Cleary TG, Obrig TG (1990) Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr Nephrol 4: 276–283PubMedCrossRefGoogle Scholar
  43. Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of haemolytic-•uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1: 619–620PubMedCrossRefGoogle Scholar
  44. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between idiopathic hemolytic uremic syndrome and infection by Verotoxinproducing Escherichia coli. J Infect Dis 151: 775–782PubMedCrossRefGoogle Scholar
  45. Karmali M, Lingwood CA, Petric M, Brunton J, Gyles C (1996) Maintaining the existing phenotype nomenclatures for E. coli cytotoxins. Amer Soc for Microbiol News 62: 167–169Google Scholar
  46. Keenan KP, Sharpnack DD, Collins H, Formal SB, O’Brien AD (1986) Morphologic evaluation of the effects of Shiga toxin and E. coli Shiga-like toxin on the rabbit intestine. Am J Pathol 125: 69–80PubMedGoogle Scholar
  47. Keusch GT, Grady GF, Mata LJ, McIver J (1972) The pathogenesis of Shigella diarrhea. 1. Enterotoxin production by Shigella dysenteriae 1. J Clin Invest 51: 1212–1218PubMedCrossRefGoogle Scholar
  48. Keusch CT, Acheson DWK, Marchant C, et al. (1998) Toxoid-based active and passive immunization to prevent and/or modulate hemolytic-uremic syndrome due to Shiga-toxin-producing ESCHERICHIA coLI. In: Kaper JB, O’Brien AD (eds )Google Scholar
  49. Escherichia coli 0157:H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 409–418Google Scholar
  50. Khine AA, Lingwood CA (1994) Capping and receptor-mediated endocvtosis of cell-bound Verotoxin (Shiga-like toxin) 1: chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. J Cell Physiol 161: 319–332PubMedCrossRefGoogle Scholar
  51. Kiarash A, Boyd B, Lingwood CA (1994) Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem 269: 11138–11146PubMedGoogle Scholar
  52. Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, Takeda T, Fujimoto.1 (1998) Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178: 178–184Google Scholar
  53. Konadu E, Parke, Jr, Donohue-Rolfe A, et al. (1998a) Synthesis and immunologic properties of 0-specific polysaccharide—protein conjugate vaccines for prevention and treatment of infections with Escherichia coli 0157 and other causes of hemolytic—uremic syndrome. In: Kaper JB, O’Brien AD (eds) Escherichia soli O157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 419–424Google Scholar
  54. Konadu EY, Parke, Jr, Tran HT, Bryla DA, Robbins JB, Szu SC (1998b) Investigational vaccine for Escherichia coli 0157: phase-1 study of 0157 0-specific polysaccharide — Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J Infect Dis 177: 383–387PubMedCrossRefGoogle Scholar
  55. Konowalchuk J, Speir JI, Stavric S (1977) Vero response to a cytotoxin of Escherichia coli. Infect Immun 18: 775–779PubMedGoogle Scholar
  56. Kraulis, PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl. Crystal. 24: 946–950Google Scholar
  57. Levine MM (1998) Immunoprophylaxis of Shiga toxin-producing Escherichia coli infection and disease: strengths and weaknesses of various strategies. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 405–408Google Scholar
  58. Levine MM, Dupont HL, Formal SB, Hornick RB, Takeuchi A, Gangarosa EJ, Snyder MJ, Libonati JP (1973) Pathogenesis of Shigella dysenteriae 1 ( Shiga) dysentery. J Infect Dis 127: 261–270Google Scholar
  59. Lindberg AA, Brown JE, Stromberg N, Westling—Ryd M, Schultz.1E, Karlson K—A (1987) Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenieriae type 1. J Biol Chem 262: 1779–1785Google Scholar
  60. Lindgren SW, Melton AR, O’Brien AD (1993) Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun 61: 3832–3842PubMedGoogle Scholar
  61. Lindgren SW, Samuel JE, Schmitt CK, O’Brien AD (1994) The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect Immun 62: 623–631PubMedGoogle Scholar
  62. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJ (1998) Structure of the Shiga-like-toxin-I B pentamer complcxed with an analogue of its receptor Gb3. Biochemistry 37: 1777–1788PubMedCrossRefGoogle Scholar
  63. Lingwood CA, Mylvaganam M, Arab S, Khine AA, Magnusson G, Grinstein S, Nyholm P-G (1998) Shiga toxin (Verotoxin) binding to its receptor glycolipid. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157:H7 and other Shiga-toxin-producing E. coli strains. ASM Press,Washington DC, pp 129–139Google Scholar
  64. Lockman H, Kaper JB (1983) Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin. J Biol Chem 258: 13722–13726PubMedGoogle Scholar
  65. Louise CB, Obrig TG (1994) Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression in vitro. Microvasc Res 47: 377–387PubMedCrossRefGoogle Scholar
  66. Louise CB, Obrig TG (1995) Specific interaction of Escherichia coli 0 157:H7-derivec Shiga-like toxin II with human renal endothelial cells. J Infect Dis 172: 1397–1401PubMedCrossRefGoogle Scholar
  67. Marques LRM, Peiris JSM, Cryz SJ, O’Brien AD (1987) Escherichia coli strains isolated from pigs with edema disease produce a variant of Shiga-like toxin 11. FEMS Microbiol Lett 44: 33–38Google Scholar
  68. McKee ML, O’Brien AD (1995) Investigation of enterohemorrhagic Escherichia coli O157:H7 adherence characteristics and invasion potential reveals a new attachment pattern shared by intestinal E. coli. Infect Immun 63: 2070–2074PubMedGoogle Scholar
  69. McKee ML, Melton-Celsa AR, Moxley RA, Francis DH, O’Brien AD (1995) Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells. Infect Immun 63: 3739–3744PubMedGoogle Scholar
  70. Mekalanos JJ, Swartz DJ, Pearson GDN, Harford N, Groyne F, De Wilde M (1983) Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306: 551–557PubMedCrossRefGoogle Scholar
  71. Melton-Celsa AR, O’Brien AD (1996) Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun 64: 1569–1576PubMedGoogle Scholar
  72. Melton-Celsa AR, O’Brien AD (1998) Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxin-producing E. coli. ASM Press, Washington DC, pp 121–128Google Scholar
  73. Menikh A, Saleh MT, Gariepy J, Boggs JM (1997) Orientation in lipid bilayers of a synthetic peptide representing the C-terminus of the Al domain of Shiga toxin. A polarized Atr-FTI R study. Biochemistry 36: 15865–15872Google Scholar
  74. Molloy SS, Thomas L, VanSlyke JK, Stenberg PE, Thomas G (1994) Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO 13: 18–33Google Scholar
  75. Muhldorfer I, Hacker J, Keusch GT, Acheson DW, Tschape H, Kane AV, Ritter A, Olschlager T, Donohue—Rolfe A (1996) Regulation of the Shiga-like-toxin-II operon in Escherichia coli. Infect Immun 64: 495–502Google Scholar
  76. Neisser M, Shiga K (1903) Ueber freie Recptoren von Typhus — and Dysenterue — Bazillen and ueber das Dysenterie Toxin. Dtsch Med Wochenschr 29: 61–62CrossRefGoogle Scholar
  77. Novillo AA, Voyer LE, Cravioto R, Freire MC, Castano G, Wainstein R, Binztein N (1988) Haemolytic uraemic syndrome associated with faecal-cytotoxin-and Verotoxin-neutralizing antibodies. Pediatr Nephrol 2: 288–290PubMedCrossRefGoogle Scholar
  78. Nyholm P-G, Magnusson G, Zheng Z, Norel R, Binnington-Boyd B, Ling-wood CA (1996) Two distinct binding sites for globotriaosylceramidc on Verotoxins: identification by molecular modeling and confirmation using deoxy analogues and a new glycolipid receptor for all Verotoxins. Chem Biol 3: 263275Google Scholar
  79. O’Brien AD, LaVeck GD (1983) Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun 40: 675–683PubMedGoogle Scholar
  80. O’Brien AD, LaVeck GD, Griffin DE, Thompson MR (1980) Characterization of Shigella dysenteriae 1 ( Shiga) toxin purified by anti-Shiga-toxin affinity chromatography. Infect Immun 30: 170–179Google Scholar
  81. O’Brien AD, Lively TA, Chen M, Rothman SW, Formal SB (1983) Escherichia coli 0157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 ( Shiga)-like cytotoxin. Lancet 1: 702Google Scholar
  82. O’Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB (1984) Shigalike-toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 226: 694–696PubMedCrossRefGoogle Scholar
  83. O’Brien AD, Marques LRM, Kerry CF, Newland JW, Holmes RK (1989) Shiga-like toxin converting phage of enterohemorrhagic Escherichia coli strain 933. Microb Pathog 6: 381–390PubMedCrossRefGoogle Scholar
  84. O’Brien AD,Tesh VL, Donohue-Rolfe A, et al (1992) Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. In: Sansonetti PJ (ed) Pathogenesis of shigellosis. Berlin Heidelberg, Springer, pp 66–94Google Scholar
  85. Obrig TG (1998) Interaction of Shiga toxins with endothelial cells. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157:H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 303–31 1Google Scholar
  86. Olitsky PK, Kligler IJ (1920) Toxins and antitoxins of Bacillus clysenteriae Shiga. J Exp Med 31: 19–36PubMedCrossRefGoogle Scholar
  87. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobajashi JM (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160: 994–998PubMedCrossRefGoogle Scholar
  88. Perera LP, Marques LRM, O’Brien AD (1988) Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol 26: 2127–2131PubMedGoogle Scholar
  89. Perera LP, Samuel JE, Holmes RK, O’Brien AD (1991) Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II essential for holotoxin activity. J Bacteriol 173: 1151–1160PubMedGoogle Scholar
  90. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargett NT, Blake PA, Cohen ML (1983) Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Eng J Med 308: 681–685CrossRefGoogle Scholar
  91. Rowe PC, Orrbine E, Lior H, Wells GA, McLaine PN (1993) A prospective study of exposure to Verotoxin-producing Escherichia coli among Canadian children with haemolytic—uraemic syndrome. Epidemiol Infect 110: 1–7PubMedCrossRefGoogle Scholar
  92. Samuel JE, Gordon VM (1994) Evidence that proteolytic separation of Shiga-liketoxin-type-IIv A subunit into A 1 and A2 subunits is not required for toxin activity. J Biol Chem 269: 4853–4859PubMedGoogle Scholar
  93. Samuel JE, Perera LP, Ward S, O’Brien AD, Ginsburg V, Krivan IIC (1990) Comparison of the glycolipid-receptor specificities of the Shiga-like-toxin-type-II and Shiga-like-toxin-type-II variants. Infect Immun 58: 611–618PubMedGoogle Scholar
  94. Sandvig K, Van Deurs B (1994) Endocytosis and intracellular sorting of ricin and Shiga toxin. FEBS Lett 346: 99–102PubMedCrossRefGoogle Scholar
  95. Sandvig K, Van Deurs B (1996) Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev 76: 949–966PubMedGoogle Scholar
  96. Sandvig K, Olsnes S, Brown JE, Petersen OW, Van Deurs B (1989) Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella clysenteriae 1. J Cell Biol 108: 1331–1343PubMedCrossRefGoogle Scholar
  97. Sandvig K, Prydz K, Ryd M, Van Deurs B (1991) Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells. J Cell Biol 113: 55. 3–562Google Scholar
  98. Sandvig K, Garred 0, Van Deurs B (1997) Intracellular transport and processing of protein toxins produced by enteric bacteria. In: Paul PS, Francis DH, Benfield DA (eds) Mechanisms in the pathogenesis of enteric diseases. Plenum Press, New York. pp 225–232Google Scholar
  99. Saxena SS, O’Brien AD, Ackerman EJ (1989) Shiga toxin, Shiga—like toxin II variant and ricin are all single-site RNA N-glycosidases of 28-S RNA when microinjectec into Xenopus oocytes. J Biol Chem 264: 596–601PubMedGoogle Scholar
  100. Schapiro FB, Lingwood C, Furuya W, Grinstein S (1998) pH-dependent retrograde’ targeting of glycolipids to the Golgi complex. Am J Physiol 274: 0319 — C332Google Scholar
  101. Schmitt CK, McKee ML, O’Brien AD (1991) Two copies of Shiga-like-toxin-II-related genes common in enterohemorrhagic Escherichia coli strains are responsible fo–the antigenic heterogeneity of the 0157:1-I strain E32511. Infect Immun 59: 1065–1073PubMedGoogle Scholar
  102. Scotland SM, Smith HR, Willshaw GA, Rowe B (1983) Vero-cytotoxin production in a strain of Escherichia coli determined by genes carried on bacteriophage. Lancet 2: 216PubMedCrossRefGoogle Scholar
  103. Scotland SM, Willshaw GA, Smith HR, Rowe B (1987) Properties of strains of Escherichia coli belonging to serogroup 0157, with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect 99: 613–624PubMedCrossRefGoogle Scholar
  104. Scotland SM, Said B, Thomas A, Rowe B (1994) Ability of human sera to neutralise the activity of Vero cytotoxins VT1, VT2 and variant forms of VT2. FEMS Microbiol Lett 115: 285–290PubMedCrossRefGoogle Scholar
  105. Siddons CA, Chapman PA (1993) Detection of serum and faecal antibodies in haem- orrhagic colitis caused by Escherichia coli 0157. J Med Microbiol 39: 408–415PubMedCrossRefGoogle Scholar
  106. Sixma TK, Stein PE, Hol WGJ, Read R (1993) Comparison of the B pentamers of heat-labile enterotoxin and Verotoxin-1: two structures with remarkable similarity and dissimilarity. Biochemistry 32: 191–198PubMedCrossRefGoogle Scholar
  107. Sjogren R, Neill R, Rachmilewitz D, Fritz D, Newland J, Sharpnack D, Colleton C, Fondacaro J, Gemski P, Boedeker E (1994) Role of Shiga-like toxin I in bacterial enteritis: comparison between isogenic Escherichia coli strains induced in rabbits. Gastroenterology 106: 306–317PubMedGoogle Scholar
  108. Smith HW, Green P, Parsell Z (1983) Vero cell toxins in Escherichia coli and related bacteria: transfer by phage and conjugation and toxic action in laboratory animals, chickens, and pigs. J Gen Microbiol 129: 3121–3137PubMedGoogle Scholar
  109. Stein PE, Boodhoo A, Tyrell GT, Brunton J, Read RJ (1992) Crystal structure of the cell-binding B oligomer of Verotoxin-1 from E. coli. Nature 355: 748–750PubMedCrossRefGoogle Scholar
  110. Strockbine NA, Marques LRM, Holmes RK, O’Brien AD (1985) Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 50: 695–700PubMedGoogle Scholar
  111. Strockbine NA, Marques LRM, Newland JW, Smith HW, Holmes RK, O’Brien AD (1986) Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 53: 135–140PubMedGoogle Scholar
  112. Strockbine NA, Jackson MP, Sung LM, Holmes RK, O’Brien AD (1988) Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J Bacteriol 170: 1116–1122PubMedGoogle Scholar
  113. Sung LM, Jackson MP, O’Brien AD, Holmes RK (1990) Analyses of transcription of the Shiga-like-toxin-type-II and Shiga-like-toxin-type-II variant operons of Escherichia coli. J Bacteriol 172: 6386–6395PubMedGoogle Scholar
  114. Takao T, Tanabe T, Hong YM, Shimonishi Y, Kurazono H, Yutsudo T, Sasakawa C, Yoshikawa M,Takeda Y (1988) Identity of molecular structure of Shiga-like toxin I (VT1) from Escherichia coli O157:H7 with that of Shiga toxin. Microb Pathog 5: 57–69Google Scholar
  115. Tauxe RV (1998) Public Health Perspective on Immunoprophylactic Strategies for Escherichia coli O157:H7: who or what would we immunize? In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 445–452Google Scholar
  116. Tesh VI, O’Brien AD (1991) The pathogenic mechanisms of Shiga toxin and the Shigalike toxins. Mol Micro 5: 1817–1822CrossRefGoogle Scholar
  117. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O’Brien AD, Samuel JE (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type Il for mice. Infect Immun 61: 3392–3402PubMedGoogle Scholar
  118. Tyre11.
    GJ, Ramotar K, Toye B, Boyd B, Lingwood CA, Brunton JL (1992) Alteration of the carbohydrate binding specificity of Verotoxins from Gala1–40a1 to GalNAcß1–3Gala1–4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci USA 89: 524–528CrossRefGoogle Scholar
  119. Van Heyningen WE, Gladstone GP (1953a) The neurotoxin of Shigella shigae. 3. The effect of iron on production of the toxin. Br J Exp Pathol 34: 221–229Google Scholar
  120. Van Heyningen WE, Gladstone GP (1953b) The neurotoxin of Shigella shigae. 1. Production, purification, and properties of the toxin. Br J Exp Pathol 34: 202–216Google Scholar
  121. Vicari G, Olitzki AL, Olitzki Z (1960) The action of the thermolabile toxin of Shigella dysenteriae on cells cultivated in vitro. Br J Exp Pathol 41: 179–189PubMedGoogle Scholar
  122. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O’Brien AD (1990) Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 58: 3959–3965PubMedGoogle Scholar
  123. Weinstein DL, Holmes RK, O’Brien AD (1988a) Effects of iron and temperature on Shiga-like-toxin-I production by Escherichia coli. Infect Immun 56:106–1l 1Google Scholar
  124. Weinstein DL, Jackson ME Samuel JE, Holmes RK, O’Brien AD (1988b) Cloning and sequencing of a Shiga-like-toxin-type-II variant from an Escherichia coli strain responsible for edema disease of swine. J Bacteriol 170: 4223–4230PubMedGoogle Scholar
  125. Whittam TS (1998) Evolution of Escherichia coli 0157:H7 and other Shiga-toxinproducing E. coli strains. In: Kaper JB, O’Brien AD (eds) Escherichia coli O157: H7 and other Shiga-toxin-producing E. coli strains. ASM Press, Washington, DC, pp 195–209Google Scholar
  126. Yamasaki S, Furutani M, Ito K, Igarashi K, Nishibuchi M,Takeda Y (1991) Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. Microb Pathog 1: I - 9Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • A. R. Melton-Celsa
  • A. D. O’Brien

There are no affiliations available

Personalised recommendations